Safety Reading Notes

Read safety context beside the research guide.

The 2-AG source set includes safety-context rows around 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 26271952

Mechanistic and preclinical research summary: insufficient (8), mechanistic or pharmacological (5), preclinical (1)

PubMed For Dummies Article

2-AG Evidence Review: the long-form source walk-through

Quick read
  • 2-AG currently has 15 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 26271952
  • The evidence classes most visible in the row language are insufficient (8), mechanistic or pharmacological (6), and preclinical (1). PMID 16086683
  • The study-design language most visible in the row language is Narrative or expert review (8), and Animal study (6). PMID 21418147
  • The repeated topics are 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva... (14), and CB2 (1), which tells the reader where to start opening PubMed and DOI links. PMID 12505686

Start with the research question

2-AG is built from 15 source-backed evidence row(s) and 15 research source(s). The current evidence classes read as insufficient (8), mechanistic or pharmacological (6), and preclinical (1), and the study-design language most often reads as Narrative or expert review (8), and Animal study (6). PMID 26271952

The row-level question is not simply whether 2-AG is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva... (14), and CB2 (1). PMID 16086683

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 16678907

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 20952498

Mechanistic evidence 6 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 12432941

Limits and uncertainty 8 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 39612328

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 24768821

Where this page has the most source density

The largest bucket surfaced for this page is 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2, which gives readers another way to see what the literature repeatedly circles. PMID 26271952

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 16086683

Bucket chapters: what the literature is circling

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

14 research sources 14 rows (1078-1091) Mechanistic and preclinical research summary: insufficient (8), mechanistic or pharmacological (5), preclinical (1)

2-AG appears in rows studying 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 14 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 26271952

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 26271952

  • Evidence row 1078

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharma... PMID 26271952

  • Evidence row 1091

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure:... PMID 38052772

CB2

1 research source 920 Mechanistic research summary: mechanistic or pharmacological (1)

2-AG appears in rows about CB2 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 16086683

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 16086683

  • Evidence row 920

    2-AG modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tis... PMID 16086683

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (6 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 26271952

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 16086683

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 36966972
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 36125319
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 33450278

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 26271952

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 16086683

Source-reading checklist for 2-AG

  1. Open the linked PubMed or DOI record. PMID 36481187
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 24676249
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 38052772
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 26271952
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 16086683

Source Notes

2-AG source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 920

    2-AG modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 16086683

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.
  2. Evidence row 1078

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26271952

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System and its Modulation by Phytocannabinoids.
  3. Evidence row 1079

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 21418147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
  4. Evidence row 1080

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12505686

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
  5. Evidence row 1081

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16678907

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
  6. Evidence row 1082

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20952498

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid overload.
  7. Evidence row 1083

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12432941

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid hydrolases.
  8. Evidence row 1084

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 39612328

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.
  9. Evidence row 1085

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24768821

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
  10. Evidence row 1086

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36966972

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.
  11. Evidence row 1087

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36125319

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.
  12. Evidence row 1088

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33450278

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.
  13. Evidence row 1089

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36481187

    Evidence class: mechanistic or pharmacological. Source: Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.
  14. Evidence row 1090

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24676249

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.
  15. Evidence row 1091

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 38052772

    Evidence class: preclinical; Study design: Animal study. Source: A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.